Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

Date publication

février 2018

Journal

The Lancet. Haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre , Pr DELMER Alain

Tous les auteurs :
Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V, ,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29275118

Résumé

Most patients with chronic lymphocytic leukaemia relapse after initial therapy combining chemotherapy with rituximab. We assessed the efficacy and safety of rituximab maintenance treatment versus observation for elderly patients in remission after front-line abbreviated induction by fludarabine, cyclophosphamide, and rituximab (FCR).

Mots clés

Aged, Female, Humans, Immunotherapy, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, Male, Rituximab, pharmacology

Référence

Lancet Haematol. 2018 Feb;5(2):e82-e94